S19-387 Novel Azapodophyllotoxin Derivatives for Treatment of Lymphoma and Kidney Cancer Researchers at Stanford have developed synthetic derivatives of a natural product, azapodophyllotoxin (AZP), that exhibit remarkable anticancer activities. Arvin Gouw Sanjay Malhotra Dean Felsher
S17-409 Compounds targeting phospholipid synthesis to treat cancer and metabolic disease Disease indication: Cancer: Renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), lymphoma and potentially other MYC-driven cancer Drug format: Small molecule compounds, alone or in combination with other chemotherapeutic drugs Arvin Gouw Dean Felsher Richard Zare Katy Margulis Feng Jin Steven Schow Robert Greenhouse David Loughhead Steven Richards
S19-257 Novel compounds inhibit phospholipid synthesis in cancer Disease indication Cancer: Renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) Drug format: Small molecule compounds, alone or in combination with other chemotherapeutic drugs Drug class: First-in-class Arvin Gouw Steven Schow Robert Greenhouse Toni Kline Dean Felsher